Tests universal CAR T cells in people with multiple myeloma in remission
Tests universal CAR T immune cells in adults with multiple myeloma in remission.
Plain-language title generated from the registry record
Registry title: Universal CAR-T Cells Targeting Multiple Myeloma
Key facts
- Where
- Shenzhen, ChinaSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06006741, who can take part
Where in China
- Shenzhen Geno-immune Medical InstituteShenzhen, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shenzhen Geno-Immune Medical Institute
- Trial code
- NCT06006741
- Record updated
- 2 November 2026
- Original description
The aim of this study is to assess the feasibility, safety and efficacy of universal CAR T cells targeting multiple myeloma. Another goal of the study is to learn more about the persistence and function of the universal CAR T cells in the body.Read full original descriptionShow less
Universal CAR-T Cells for the Treatment of Multiple Myeloma
The aim of this study is to assess the feasibility, safety and efficacy of universal CAR T cells targeting multiple myeloma. Another goal of the study is to learn more about the persistence and function of the universal CAR T cells in the body.
Inclusion: Patients with confirmed multiple myeloma failed curative treatment options (including autologous or allogeneic SCT); Complete remission (CR) cannot be achieved after at least 2 prior therapy regimens; High risk MM in CR1 or CR2 and not eligible for SCT because of age or comorbid diseases; Less than 1 year between last chemotherapy and progression (i.e. most recent progression free interval < 1 year); Relapsed after prior autologous or allogenic SCT with residual disease after at least 1 prior therapy and not eligible for allogeneic SCT; Residual disease after primary therapy and not eligible for ASCT; Expected survival > 12 weeks• Creatinine < 2.5 mg/dl• ALT (alanine aminotransferase)/AST (aspartate aminotransferase) < 3x normal; Bilirubin < 2.0 mg/dl; Any relapse after prior SCT is eligible regardless of other prior therapy; Adequate venous access for apheresis, and no other contraindications for leukapheresis; Voluntary informed consent is signed.
Exclusion: Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary; Previous related CAR-T cell therapy; Uncontrolled active infection; Active hepatitis B or hepatitis C infection; Any uncontrolled active medical disorder that would preclude participation; HIV infection; Pregnant or lactating women.